CN103110686A - 一种治疗糖尿病性视网膜病变的药物及其制备方法 - Google Patents
一种治疗糖尿病性视网膜病变的药物及其制备方法 Download PDFInfo
- Publication number
- CN103110686A CN103110686A CN2013100435422A CN201310043542A CN103110686A CN 103110686 A CN103110686 A CN 103110686A CN 2013100435422 A CN2013100435422 A CN 2013100435422A CN 201310043542 A CN201310043542 A CN 201310043542A CN 103110686 A CN103110686 A CN 103110686A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- diabetic retinopathy
- group
- softgel shell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 54
- 206010012689 Diabetic retinopathy Diseases 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 229940079593 drug Drugs 0.000 title description 13
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 9
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 8
- 239000004014 plasticizer Substances 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000049 pigment Substances 0.000 claims abstract description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000007903 gelatin capsule Substances 0.000 claims description 8
- 230000002421 anti-septic effect Effects 0.000 claims description 7
- 235000019209 bilberry extract Nutrition 0.000 claims description 7
- 239000006184 cosolvent Substances 0.000 claims description 7
- 239000000375 suspending agent Substances 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 239000002390 adhesive tape Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 3
- 229940102480 bilberry extract Drugs 0.000 claims description 3
- 239000007766 cera flava Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 3
- 239000003292 glue Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 3
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- 239000004250 tert-Butylhydroquinone Substances 0.000 claims description 3
- 235000019281 tert-butylhydroquinone Nutrition 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 2
- 229960002233 benzalkonium bromide Drugs 0.000 claims description 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 229960004365 benzoic acid Drugs 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 2
- 229960004926 chlorobutanol Drugs 0.000 claims description 2
- 239000000084 colloidal system Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 238000009413 insulation Methods 0.000 claims description 2
- 229960003511 macrogol Drugs 0.000 claims description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 235000010235 potassium benzoate Nutrition 0.000 claims description 2
- 239000004300 potassium benzoate Substances 0.000 claims description 2
- 229940103091 potassium benzoate Drugs 0.000 claims description 2
- 239000000473 propyl gallate Substances 0.000 claims description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 229960003885 sodium benzoate Drugs 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000008961 swelling Effects 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 239000000284 extract Substances 0.000 abstract description 3
- JYXWNSQXDWWFEW-CHFPMYPESA-N Renieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2ccc(C)c(C)c2C JYXWNSQXDWWFEW-CHFPMYPESA-N 0.000 abstract 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 abstract 1
- 244000078534 Vaccinium myrtillus Species 0.000 abstract 1
- 229960000074 biopharmaceutical Drugs 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- SYUXAJSOZXEFPP-UHFFFAOYSA-N glutin Natural products COc1c(O)cc2OC(=CC(=O)c2c1O)c3ccccc3OC4OC(CO)C(O)C(O)C4O SYUXAJSOZXEFPP-UHFFFAOYSA-N 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 21
- 239000007901 soft capsule Substances 0.000 description 10
- 210000001525 retina Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 229960003180 glutathione Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 208000032253 retinal ischemia Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000002177 Cataract Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 206010020710 Hyperphagia Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000017442 Retinal disease Diseases 0.000 description 3
- 206010038923 Retinopathy Diseases 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 206010036067 polydipsia Diseases 0.000 description 3
- 208000022530 polyphagia Diseases 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000001210 retinal vessel Anatomy 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- QGNBTYAQAPLTMX-UHFFFAOYSA-L calcium dobesilate Chemical compound [Ca+2].OC1=CC=C(O)C(S([O-])(=O)=O)=C1.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 QGNBTYAQAPLTMX-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000003668 pericyte Anatomy 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000004382 visual function Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000002687 Caesalpinia echinata Nutrition 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 206010063341 Metamorphopsia Diseases 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000127464 Paubrasilia echinata Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010038491 Renal papillary necrosis Diseases 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004155 blood-retinal barrier Anatomy 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000004300 dark adaptation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 208000027993 eye symptom Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组别 | 动物数 | E/P比值 |
A组 | 10 | 1.25±0.01 |
B组 | 10 | 2.41±0.12** |
C组 | 10 | 1.68±0.07## |
D组 | 10 | 1.86±0.11## |
组别 | 动物数 | MDA(nmol/mgprot) | GSH(nmol/gprot) | SOD(NU/mgprot) |
A组 | 10 | 3.61±0.37 | 99.20±9.26 | 105.86±8.64 |
B组 | 10 | 10.99±0.65** | 54.13±5.89** | 50.37±6.42** |
C组 | 10 | 9.33±0.41## | 76.39±6.13## | 89.03±7.11## |
D组 | 10 | 9.46±0.52## | 70.88±6.35## | 86.53±6.97## |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310043542.2A CN103110686B (zh) | 2013-02-04 | 2013-02-04 | 一种治疗糖尿病性视网膜病变的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310043542.2A CN103110686B (zh) | 2013-02-04 | 2013-02-04 | 一种治疗糖尿病性视网膜病变的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103110686A true CN103110686A (zh) | 2013-05-22 |
CN103110686B CN103110686B (zh) | 2016-03-23 |
Family
ID=48409088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310043542.2A Expired - Fee Related CN103110686B (zh) | 2013-02-04 | 2013-02-04 | 一种治疗糖尿病性视网膜病变的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103110686B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1909916A (zh) * | 2004-01-16 | 2007-02-07 | 亚美利技术股份有限公司 | 含有越桔提取物的泡腾组合物 |
CN1915337A (zh) * | 2006-08-18 | 2007-02-21 | 孙天民 | 一种糖尿病患的护目胶囊 |
CN101468059A (zh) * | 2007-12-28 | 2009-07-01 | 天津市中宝制药有限公司 | 治疗近视的凝胶贴剂及其制备方法 |
CN101951899A (zh) * | 2008-01-18 | 2011-01-19 | 霍法格研究(卢森堡)控股公司 | 异常眼内压治疗 |
CN102008488A (zh) * | 2010-11-24 | 2011-04-13 | 广州固志医药科技有限公司 | 一种曲安奈德眼用制剂及其制备方法 |
-
2013
- 2013-02-04 CN CN201310043542.2A patent/CN103110686B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1909916A (zh) * | 2004-01-16 | 2007-02-07 | 亚美利技术股份有限公司 | 含有越桔提取物的泡腾组合物 |
CN1915337A (zh) * | 2006-08-18 | 2007-02-21 | 孙天民 | 一种糖尿病患的护目胶囊 |
CN101468059A (zh) * | 2007-12-28 | 2009-07-01 | 天津市中宝制药有限公司 | 治疗近视的凝胶贴剂及其制备方法 |
CN101951899A (zh) * | 2008-01-18 | 2011-01-19 | 霍法格研究(卢森堡)控股公司 | 异常眼内压治疗 |
CN102008488A (zh) * | 2010-11-24 | 2011-04-13 | 广州固志医药科技有限公司 | 一种曲安奈德眼用制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103110686B (zh) | 2016-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shim et al. | Ginkgo biloba extract and bilberry anthocyanins improve visual function in patients with normal tension glaucoma | |
US9265809B2 (en) | Methods and compositions for treating and preventing signs or symptoms of eye disease | |
CN103735733B (zh) | 一种含叶黄素酯的复方制剂及其制备方法 | |
CN106236739B (zh) | 含有叶黄素/叶黄素酯的组合物及其应用 | |
CN102225087A (zh) | 一种强效护眼的叶黄素复方制剂 | |
CN103417733B (zh) | 一种缓解视疲劳的药物组合物 | |
CN103566049A (zh) | 用于提高眼睛中视黄斑色素密度并预防或治疗年龄相关性视黄斑衰退症的组合物 | |
CN102960738A (zh) | 越橘叶黄素软胶囊及其制备方法 | |
WO2018205961A1 (zh) | 一种用于治疗干眼的滴眼液 | |
CN100574772C (zh) | 一种含叶黄素的软胶囊及其制备方法 | |
CN106721835A (zh) | 一种缓解视疲劳的固体饮料 | |
CN102100693A (zh) | 一种含有肌肽的人工泪液及其制备方法 | |
Choo et al. | Review of evidence for the usage of antioxidants for eye aging | |
CN103316032B (zh) | 含有羟基酪醇的组合物及其应用 | |
CN104257727A (zh) | 缓解视疲劳软胶囊及加工方法 | |
CN105520137B (zh) | 一种具有缓解视疲劳和保护视力功能的保健食品 | |
CN105595341A (zh) | 一种具有抗氧化、缓解视疲劳的番茄红素组合物 | |
CN102166205B (zh) | 丹皮酚及其衍生物的医药用途 | |
CN102038644A (zh) | 叶黄素水溶性粉末及其制备工艺 | |
WO2012079419A1 (zh) | 一种治疗黄斑变性的药物组合物 | |
CN103110686B (zh) | 一种治疗糖尿病性视网膜病变的药物及其制备方法 | |
CN103599340B (zh) | 治疗和预防糖尿病及其眼并发症的药物组合物及其应用 | |
CN111450054A (zh) | 一种含有咖啡酸酯的眼用制剂、制备方法及应用 | |
CN101278940A (zh) | 用于治疗糖尿病性心血管病变的药物组合物及其制备方法 | |
CN102218083A (zh) | 一种治疗和预防眼科疾病的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161216 Address after: 510000 Guangdong city of Guangzhou Province Economic and Technological Development Zone of Guangzhou Science City on Road No. 80, Guangzhou technology innovation base C District sixth floor Patentee after: Guangzhou Huahai Pharmaceutical Co., Ltd. Address before: 510000 Guangdong city of Guangzhou Province Economic and Technological Development Zone of Guangzhou Science City on Road No. 80, Guangzhou technology innovation base C District sixth floor Patentee before: Guangzhou Huahai Pharmaceutical Co., Ltd. Patentee before: Huizhou City Baijirui Medical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160323 Termination date: 20210204 |